Kaj Blennow is a prominent figure in neuroscience and clinical chemistry, widely recognized for his groundbreaking work on biomarkers in neurodegenerative diseases. He is a professor of Clinical Neurochemistry at the University of Gothenburg, Sweden, and serves as the Head of the Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital. With a medical degree and a PhD in neurochemistry, Blennow has dedicated his career to advancing the understanding and diagnosis of disorders such as Alzheimer's disease.

Blennow's research focuses on the development of cerebrospinal fluid (CSF) and blood biomarkers to improve early and accurate detection of neurodegenerative diseases. He has played a pivotal role in establishing β-amyloid, tau, and phosphorylated tau as hallmark biomarkers for Alzheimer's disease, significantly influencing both research and clinical practice.

With over 2000 peer-reviewed publications, Blennow is one of the most cited researchers in the field, reflecting his extensive contributions. He has received numerous awards for his work, including recognition from the European Federation of Clinical Chemistry and Laboratory Medicine. Beyond research, Blennow actively collaborates with pharmaceutical companies to develop diagnostic tools and treatments, making him a vital figure in the fight against neurodegenerative diseases.